

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the Application. Deletions are ~~strikethrough~~ and additions are underlined.

**Listing of Claims:**

1. (Currently amended) A composition comprising ~~annatto extract and at least one ingredient selected from the group consisting of tocotrienol containing material and non-tocotrienol containing material, wherein greater than 60% of the tocotrienols are tocotrienols an oily byproduct of Bixa orellana seed containing a tocotrienol where the ratio of delta-tocotrienol to gamma-tocotrienol is between 1:25 to 25:1.~~
- 2-24. (Canceled)
25. (Currently amended) ~~A-The composition of Claim 1, further comprising annatto extract and~~ at least one ingredient selected from the group consisting of phytosterols, oryzanol, policosanols, pentathine, red yeast rice (*Monascus*), oat bran, garlic, gugul lipids, chitosan, soy protein (e.g., oligo- and poly-peptides, hydrolysates), CoQ10, carnitine, magnesium, calcium, D-tyroxine, fibers (insoluble and soluble types, including beta-glucans), omega-3s (DHAs and EPAs, alpha linoleic acid), lecithin, banaba extract (including corosolic acid), lipoic acids (all isomeric forms), chromium (all compounded forms), and B vitamins (including niacin).
26. (Withdrawn-Previously presented) A method to produce a beneficial effect comprising administering the composition of Claim 1 to a mammal in need of a beneficial effect.
27. (Canceled)
28. (Withdrawn-Previously presented) The method of Claim 26, where the beneficial effect is a decrease in blood levels of triglycerides.

29. (Withdrawn-Currently amended) The method of Claim 28, where the beneficial effect of the decrease in blood levels of triglycerides is ~~at least one selected from the group consisting of reversal of insulin resistance, metabolic syndrome, prediabetes, diabetes and diabetes related cardiovascular disease.~~

30. (Withdrawn-Previously presented) The method of Claim 26, where the beneficial effect treats a malady effecting the central nervous system.

31-36. (Canceled)

37. (New) The composition of Claim 1, where the ratio of delta-tocotrienol to gamma-tocotrienol is between 1:10 to 10:1.

38. (New) The composition of Claim 37, where the ratio of delta-tocotrienol to gamma-tocotrienol is 1:1.

39. (New) A composition comprising an oily byproduct extract of *Bixa orellana* seed and a natural extract where the level of tocopherol is  $\leq 50\%$ .

40. (New) The composition of Claim 39 where the level of tocopherol is  $\leq 20\%$ .

41. (New) The composition of Claim 40 where the level of tocopherol is  $\leq 1\%$ .

42. (New) The composition of Claim 39 where the natural extract is selected from the group consisting of a vegetable oil of rice bran, palm, cranberry seed, and litchi seed.

43. (New) The composition of Claim 39 where the tocopherol comprises alpha-tocopherol.

44. (New) The composition of Claim 43 where alpha-tocopherol comprises  $\leq 50\%$  of the tocopherols in the composition.

45. (New) The composition of Claim 44 where alpha-tocopherol comprises  $\leq 25\%$  of the tocopherols in the composition.

46. (New) The composition of Claim 45 where alpha-tocopherol comprises  $\leq 1\%$  of the tocopherols in the composition.

47. (New) A composition of an oily byproduct extract of *Bixa orellana* seed and a natural extract where delta-tocotrienol and gamma-tocotrienol comprise  $\geq 50\%$  of the tocotrienols in the composition.

48. (New) The composition of Claim 47 where delta-tocotrienol comprises  $\geq 50\%$  of the tocotrienols in the composition.

49. (New) A composition of an oily byproduct extract of *Bixa orellana* seed and a natural extract where C5 unsubstituted tocotrienols are  $\geq 60\%$ , and tocopherols are  $\leq 15\%$ .

50. (New) The composition of Claim 49 where the C5 unsubstituted tocotrienols are  $\geq 80\%$  and  $\leq 5\%$  tocopherols.